EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study

Ismail Karluka iD, Mustafa Mazıcan iD

Diagnostics · 16.05.2025 · 15 (10) · 1266

DOI: 10.3390/diagnostics15101266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.05.2025. Verfasst von Ismail Karluka und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Adana Dr. Turgut Noyan Application and Research Center, Baskent University, Adana 01250, Turkey. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to evaluate the efficacy and safety of the Angio-Seal™ VIP vascular closure device (VCD) in achieving hemostasis following percutaneous transhepatic portal venous interventions.

Methods

This retrospective study evaluated 20 patients (mean age: 52.85 ± 16.18 years; 80% male) who underwent percutaneous transhepatic portal vein interventions followed by tract closure with the Angio-Seal™ device between January 2016 and September 2024. Procedural data, pre- and post-procedural hemoglobin and hematocrit levels, and complications were analyzed. Technical success was defined as the successful deployment of the device with immediate hemostasis and no evidence of bleeding on post-procedural imaging.

Results

Technical success, as defined in this study, was achieved in all 20 procedures (100%). The mean hemoglobin level declined from 11.91 ± 2.01 g/dL to 11.09 ± 2.19 g/dL (p < 0.001), and the mean hematocrit level decreased from 36.18 ± 6.03% to 32.98 ± 5.80% (p = 0.001). A hemoglobin drop ≥2 g/dL occurred in two patients (10%) and a hematocrit drop ≥4% in six patients (30%); none were associated with imaging or clinical evidence of hemorrhage. No major complications were observed. Minor complications, including localized pain managed with analgesics, occurred in five patients (25%). Follow-up imaging confirmed the absence of hemoperitoneum or device-related failure.

Conclusions

Angio-Seal™ is a technically feasible, safe, and effective option for tract closure following percutaneous transhepatic portal vein access. This single-device approach may offer a cost-effective alternative to traditional embolization techniques. However, more extensive prospective studies are required to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

Angio-Seal™hemostasisinterventional radiologypercutaneous transhepatic accessportal veinportal vein thrombosisprocedure-related complicationstechnical successtract embolizationvascular closure device

Autor:innen und Institutionen

  • Department of Interventional Radiology, Adana Dr. Turgut Noyan Application and Research Center, Baskent University, Adana 01250, Turkey.

ORCID-Profile: Ismail Karluka, Mustafa Mazıcan

Zitieren

APA

Karluka, I., & Mazıcan, M. (2025). Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study. Diagnostics, 15(10), 1266. https://doi.org/10.3390/diagnostics15101266

Vancouver

Karluka I, Mazıcan M. Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study. Diagnostics. 2025;15(10):1266. doi:10.3390/diagnostics15101266

BibTeX
@article{Karluka2025,
  author = {Karluka, Ismail and Mazıcan, Mustafa},
  title = {Single Angio-Seal™ Device as a Simplified and Technically Feasible Alternative for Tract Closure in Percutaneous Portal Vein Access: A Retrospective Study},
  journal = {Diagnostics},
  year = {2025},
  volume = {15},
  number = {10},
  pages = {1266},
  doi = {10.3390/diagnostics15101266}
}
Kostenlos starten →